source
- FDA approves vepdegestrant for ESR1-mutated ER-positive advanced breast cancerOn May 1, 2026 the FDA gave its first approval to vepdegestrant, an oral selective estrogen receptor degrader, for adult patients with estrogen receptor-positive, HER2-negative breast cancer that c…
- FDA chief Marty Makary resigns, ending turbulent tenureFDA chief Marty Makary has resigned, ending a tenure described as turbulent with leadership upheaval, mass layoffs, political pressure and public disputes with drugmakers. President Trump announce…